| Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice V Hurez, V Dao, A Liu, S Pandeswara, J Gelfond, L Sun, M Bergman, ... Aging cell 14 (6), 945-956, 2015 | 105 | 2015 |
| Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients SS Kwek, V Dao, R Roy, Y Hou, D Alajajian, JP Simko, EJ Small, L Fong The Journal of Immunology 189 (7), 3759-3766, 2012 | 92 | 2012 |
| An aberrant prostate antigen–specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans Y Hou, J DeVoss, V Dao, S Kwek, JP Simko, DG McNeel, MS Anderson, ... The Journal of clinical investigation 119 (7), 2031-2041, 2009 | 76 | 2009 |
| Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells V Dao, Y Liu, S Pandeswara, RS Svatek, JA Gelfond, A Liu, V Hurez, ... Cancer Research 76 (20), 5970-5982, 2016 | 37 | 2016 |
| Systemic GM-CSF recruits effector T cells into the tumor microenvironment in localized prostate cancer XX Wei, S Chan, S Kwek, J Lewis, V Dao, L Zhang, MR Cooperberg, ... Cancer Immunology Research 4 (11), 948-958, 2016 | 34 | 2016 |
| Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage V Dao, S Pandeswara, Y Liu, V Hurez, S Dodds, D Callaway, AJ Liu, ... Cancer Prevention Research, canprevres. 0313.2014, 2015 | 23 | 2015 |
| Biphasic rapamycin effects in lymphoma and carcinoma treatment Y Liu, S Pandeswara, V Dao, Á Padrón, JM Drerup, S Lao, A Liu, V Hurez, ... Cancer Research, canres. 1140.2016, 2016 | 14 | 2016 |
| Applied neuroanatomy elective to reinforce and promote engagement with neurosensory pathways using interactive and artistic activities V Dao, PH Yeh, KS Vogel, CM Moore Anatomical sciences education 8 (2), 166-174, 2015 | 9 | 2015 |
| Neoadjuvant immunotherapy for prostate cancer with GM-CSF and tumor infiltration by antigen presenting cells L Fong, V Dao, S O'Brien, J Simko, VK Weinberg, C Ryan, JE Rosenberg, ... Journal of Clinical Oncology 26 (15_suppl), 3063-3063, 2008 | 4 | 2008 |
| Age-related gut dysbiosis contributes to age-related colitis and colon cancer risk and appears B7-H1-dependent.(HUM8P. 352) K Cardenas, V Dao, V Hurez, T Curiel The Journal of Immunology 192 (1 Supplement), 185.27-185.27, 2014 | 2 | 2014 |
| Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade. L Fong, S Kwek, V Dao, R Roy, Y Hou, J Simko, EJ Small Journal of Clinical Oncology 28 (15_suppl), 2578-2578, 2010 | 2 | 2010 |
| Denileukin diftitox reduces EL4 lymphoma growth by depleting regulatory T cells, which can be improved by αICOS (VAC12P. 1116) Y Liu, A Padron, J Drerup, V Dao, A Liu, V Hurez, T Curiel The Journal of Immunology 194 (1 Supplement), 213.7-213.7, 2015 | 1 | 2015 |
| 35: Oral rapamycin prevents carcinogen and inflammation-induced skin carcinogenesis through an IFN-γ-dependent mechanism V Dao, SL Pandeswara, K Cardenas, V Hurez, S Dodds, Y Liu, A Liu, ... Cytokine 70 (1), 36, 2014 | 1 | 2014 |
| Microencapulated rapamycin prevents carcinogen and inflammation driven colon cancer through immune mechanisms VA Dao, K Cardenas, S Lao, Á Padrón, EP Hasty, ZD Sharp, V Hurez, ... The Journal of Immunology 196 (1 Supplement), 73.9-73.9, 2016 | | 2016 |
| Rapamycin directly inhibits T cell lymphoma proliferation at high doses and facilitates immune-independent toxin-mediated killing at a low dose in vivo. Y Liu, S Pandeswara, VA Dao, Á Padrón, V Hurez, TJ Curiel The Journal of Immunology 196 (1 Supplement), 75.19-75.19, 2016 | | 2016 |
| Recruitment of effector T cells into the tumor rim and center with neoadjuvant systemic GM-CSF in patients with localized prostate cancer XX Wei, S Chan, J Lewis, S Kwek, V Dao, L Fong Cancer Research 75 (15 Supplement), 276-276, 2015 | | 2015 |
| Oral rapamycin (eRapa) requires IFN-γ and promotes γδ T cell cytotoxicity to prevent carcinogen and inflammation-induced dermal cancer (TUM9P. 1003) V Dao, S Pandeswara, Y Liu, V Hurez, A Liu, T Curiel The Journal of Immunology 194 (1 Supplement), 210.5-210.5, 2015 | | 2015 |
| Mammalian target of rapamycin inhibition with enterically given rapamycin alters immunity and gut flora in young and aged wild type mice and extends life of immunodeficient … V Hurez, V Dao, A Liu, S Pandeswara, J Gelfond, L Sun, R Svatek, ... The Journal of Immunology 194 (1 Supplement), 129.16-129.16, 2015 | | 2015 |
| Mammalian target of rapamycin inhibitors are promising T cell lymphoma treatment agents that synergize with ERβ agonists in vitro but not in vivo (VAC3P. 1061) Y Liu, G Sareddy, S Pandeswara, V Dao, C Clark, A Liu, R Vadlamudi, ... The Journal of Immunology 194 (1 Supplement), 71.8-71.8, 2015 | | 2015 |
| Oral rapamycin (eRapa) prevents carcinogen and inflammation-induced dermal cancer through immune and DNA damage mechanisms V Dao THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO, 2015 | | 2015 |
